CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Hospital Universitario La Paz
Madrid, EspañaHospital Universitario La Paz-ko ikertzaileekin lankidetzan egindako argitalpenak (37)
2021
-
Non-inflammatory causes of emergency consultation in patients with multiple sclerosis
Neurologia, Vol. 36, Núm. 6, pp. 403-411
-
Risk and outcomes of COVID-19 in patients with multiple sclerosis
European Journal of Neurology, Vol. 28, Núm. 11, pp. 3712-3721
2020
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder
Multiple Sclerosis and Related Disorders, Vol. 38
2019
-
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Multiple Sclerosis and Related Disorders, Vol. 28, pp. 235-243
2017
-
Multimarker risk stratification approach at multiple sclerosis onset
Clinical Immunology, Vol. 181, pp. 43-50
-
Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response
Brain, Vol. 140, Núm. 9, pp. 2426-2443
2016
-
Intervenciones psicoterapéuticas y psicosociales para el manejo del estrés en esclerosis múltiple: Aportación de intervenciones basadas en mindfulness
Neurologia
-
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus
Neurology: Neuroimmunology and NeuroInflammation, Vol. 3, Núm. 3
-
Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score
Revista de Neurologia, Vol. 63, Núm. 4, pp. 145-150
2015
2013
-
Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: A multicenter study
Journal of Neurology, Vol. 260, Núm. 5, pp. 1258-1262
-
Monitoring neuromyelitis optica activity.
Expert review of neurotherapeutics, Vol. 13, Núm. 9, pp. 989-999
2012
-
Clinical efficacy and effectiveness of Sativex ®, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
Expert Review of Neurotherapeutics
-
Clinically isolated syndromes suggestive of multiple sclerosis: An optical coherence tomography study
PLoS ONE, Vol. 7, Núm. 3
-
Consenso español sobre la utilización de natalizumab (Tysabri®) - 2011
Neurologia
-
Country, sex, edss change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome
PLoS ONE, Vol. 7, Núm. 6
-
Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis
PLoS ONE, Vol. 7, Núm. 10
-
Improving patient-physician dialog: Commentary on the results of the MS Choices survey
Patient Preference and Adherence
-
Increasing age at disability milestones among MS patients in the MSBase Registry
Journal of the Neurological Sciences, Vol. 318, Núm. 1-2, pp. 94-99
-
Natalizumab treatment of multiple sclerosis in Spain: Results of an extensive observational study
Journal of Neurology, Vol. 259, Núm. 9, pp. 1814-1823